212 related articles for article (PubMed ID: 29173779)
1. Development of Drug Therapies for Newborns and Children: The Scientific and Regulatory Imperatives.
Mulugeta YL; Zajicek A; Barrett J; Sachs HC; McCune S; Sinha V; Yao L
Pediatr Clin North Am; 2017 Dec; 64(6):1185-1196. PubMed ID: 29173779
[TBL] [Abstract][Full Text] [Related]
2. Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.
Mulugeta Y; Barrett JS; Nelson R; Eshete AT; Mushtaq A; Yao L; Glasgow N; Mulberg AE; Gonzalez D; Green D; Florian J; Krudys K; Seo S; Kim I; Chilukuri D; Burckart GJ
J Clin Pharmacol; 2016 Nov; 56(11):1326-1334. PubMed ID: 27040726
[TBL] [Abstract][Full Text] [Related]
3. Extrapolation of adult data and other data in pediatric drug-development programs.
Dunne J; Rodriguez WJ; Murphy MD; Beasley BN; Burckart GJ; Filie JD; Lewis LL; Sachs HC; Sheridan PH; Starke P; Yao LP
Pediatrics; 2011 Nov; 128(5):e1242-9. PubMed ID: 22025597
[TBL] [Abstract][Full Text] [Related]
4. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
[TBL] [Abstract][Full Text] [Related]
5. Bridging Adult Experience to Pediatrics in Oncology Drug Development.
Leong R; Zhao H; Reaman G; Liu Q; Wang Y; Stewart CF; Burckart G
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S129-S135. PubMed ID: 28921643
[TBL] [Abstract][Full Text] [Related]
6. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
Roberts R; Rodriguez W; Murphy D; Crescenzi T
JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
[TBL] [Abstract][Full Text] [Related]
7. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
8. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Ren Z; Zajicek A
Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
[TBL] [Abstract][Full Text] [Related]
9. The Meanings of "Pediatric Drug Development".
Rose K; Grant-Kels JM
Ther Innov Regul Sci; 2019 Nov; 53(6):767-774. PubMed ID: 30526039
[TBL] [Abstract][Full Text] [Related]
10. [What's new in pediatric pharmacology?].
Tréluyer JM; Pons G
Arch Pediatr; 2000 Dec; 7(12):1330-8. PubMed ID: 11147070
[TBL] [Abstract][Full Text] [Related]
11. The pediatric studies initiative: after 15 years have we reached the limits of the law?
Milne CP; Davis J
Clin Ther; 2014 Feb; 36(2):156-62. PubMed ID: 24529287
[TBL] [Abstract][Full Text] [Related]
12. Incorporating Innovative Techniques Toward Extrapolation and Efficient Pediatric Drug Development.
Gamalo-Siebers M; Hampson L; Kordy K; Weber S; Nelson RM; Portman R
Ther Innov Regul Sci; 2019 Sep; 53(5):567-578. PubMed ID: 31084211
[TBL] [Abstract][Full Text] [Related]
13. Newborns and drug studies: the NICHD/FDA newborn drug development initiative.
Giacoia GP; Mattison DR
Clin Ther; 2005 Jun; 27(6):796-813. PubMed ID: 16117987
[TBL] [Abstract][Full Text] [Related]
14. Steps toward harmonization for clinical development of medicines in pediatric ulcerative colitis-a global scientific discussion, part 2: data extrapolation, trial design, and pharmacokinetics.
Sun H; Vesely R; Nelson RM; Taminiau J; Szitanyi P; Isaac M; Klein A; Uzu S; Griebel D; Mulberg AE;
J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):684-8. PubMed ID: 24866782
[TBL] [Abstract][Full Text] [Related]
15. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
Corriol-Rohou S; Cheung SYA
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
[TBL] [Abstract][Full Text] [Related]
16. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
17. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop.
Berde CB; Walco GA; Krane EJ; Anand KJ; Aranda JV; Craig KD; Dampier CD; Finkel JC; Grabois M; Johnston C; Lantos J; Lebel A; Maxwell LG; McGrath P; Oberlander TF; Schanberg LE; Stevens B; Taddio A; von Baeyer CL; Yaster M; Zempsky WT
Pediatrics; 2012 Feb; 129(2):354-64. PubMed ID: 22250028
[TBL] [Abstract][Full Text] [Related]
18. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020.
Green FG; Park K; Burckart GJ
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S28-S35. PubMed ID: 34185898
[TBL] [Abstract][Full Text] [Related]
19. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
Rivera DR; Hartzema AG
Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
[TBL] [Abstract][Full Text] [Related]
20. Pediatric Efficacy Extrapolation in Drug Development Submitted to the US Food and Drug Administration 2015-2020.
Samuels S; Park K; Bhatt-Mehta V; Sun H; Mulugeta Y; Yao L; Green DJ; Burckart GJ
J Clin Pharmacol; 2023 Mar; 63(3):307-313. PubMed ID: 36150423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
